



CS/NSE&BSE/UFR/2019-20
November 14, 2019

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 14th November, 2019, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS for the quarter and half-year ended 30th September, 2019.

We are enclosing herewith the following documents:

- a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter and half-year ended 30th September, 2019
- b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and
- c) A copy of the Press Release of our company

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 13:10 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read "K Hanumantha Rao".

K Hanumantha Rao
Company Secretary

Encl: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Rs. In Lakhs

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 6 MONTHS PERIOD ENDED 30th Sept ' 2019

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended
		30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Income						
	Revenue from operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
	Other Income	558.52	300.67	658.63	859.19	1,471.40	2,422.93
	Total income	27,990.01	20,199.30	9,610.81	48,189.31	29,589.80	68,773.37
2	Expenses						
	a) Cost of materials consumed	6,047.63	5,866.31	4,102.39	11,913.94	7,961.69	20,413.82
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,057.82	(1,732.14)	(3,525.10)	1,325.68	(929.28)	(3,061.41)
	d) Employee benefits expense	1,684.58	1,875.41	1,398.33	3,559.99	3,113.15	6,347.79
	e) Finance costs	185.41	130.75	59.09	316.16	165.88	376.31
	f) Depreciation and amortisation expense	559.08	555.03	556.05	1,114.11	1,106.86	2,214.05
	g) Manufacturing Exps	2,762.42	2,534.68	2,493.06	5,297.10	4,778.56	9,982.32
	h) R & D Exps	1,466.43	1,310.14	1,238.73	2,776.57	2,837.60	6,027.60
	i) Other Expenses	1,359.16	1,040.96	803.29	2,400.12	2,092.10	4,286.59
	Total expenses	17,122.53	11,581.14	7,125.84	28,703.67	21,126.56	46,587.07
3	Profit before exceptional items & Tax (1-2)	10,867.48	8,618.16	2,484.97	19,485.64	8,463.24	22,186.30
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	10,867.48	8,618.16	2,484.97	19,485.64	8,463.24	22,186.30
6	Tax Expenses						
	a) Current tax	3,646.51	3,483.61	513.83	7,130.12	1,762.97	4,604.23
	b) Deferred tax	(10.94)	(583.22)	170.17	(594.16)	1,015.09	2,575.78
7	Net Profit/ (Loss) for the period/year(5-6)	7,231.91	5,717.77	1,800.97	12,949.68	5,685.18	15,006.29
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(5.29)	(5.29)	(10.59)	(10.58)	(21.17)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.85	1.85	3.67	3.70	7.33	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(3.44)	(3.44)	(6.92)	(6.88)	(13.84)	(13.77)
9	Total Comprehensive Income for the period (7+8)	7,228.47	5,714.33	1,794.05	12,942.80	5,671.34	14,992.52
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	111,030.80	103,802.33	91,068.49	111,030.80	91,068.49	98,088.00
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	5.68	4.49	1.41	10.17	4.47	11.79
	b) Diluted	5.68	4.49	1.41	10.17	4.47	11.79
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	



SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES							Rs. In Lakhs
PART - II		STANDALONE					
PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended	
	30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019	
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
1	SEGMENT REVENUE :-						
	a) Manufacturing (CRAMS)	26,709.93	19,616.35	8,087.96	46,326.28	26,112.18	61,362.91
	b) Services (DDDSS)	721.56	282.28	864.22	1,003.84	2,006.22	4,987.53
	c) Research & Development	-	-	-	-	-	-
	TOTAL	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
	Less Inter segment Revenue	-	-	-	-	-	-
	Net Sales from Operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
2	SEGMENT RESULTS :-						
	Profit/(Loss) before tax and interest:						
	a) Manufacturing (CRAMS)	12,541.33	10,587.58	3,252.05	23,128.91	10,338.79	26,594.91
	b) Services (DDDSS)	100.53	60.20	440.55	160.73	1,201.70	2,558.00
	c) Research & Development	(1,466.42)	(1,310.15)	(1,238.71)	(2,776.57)	(2,837.59)	(6,027.60)
	TOTAL	11,175.44	9,337.63	2,453.89	20,513.07	8,702.90	23,125.31
Less:	i) Interest	69.85	46.41	62.29	116.26	98.26	199.02
	ii) Other Un-allocable expenditure/(Income). net	238.11	673.06	(93.37)	911.17	141.40	739.99
	Total Profit Before Tax	10,867.48	8,618.16	2,484.97	19,485.64	8,463.24	22,186.30
3	SEGMENT ASSETS :						
	a) Manufacturing (CRAMS)	74,332.00	72,577.41	57,618.63	74,332.00	57,618.63	69,666.60
	b) Services (DDDSS)	5,675.23	5,629.15	3,767.31	5,675.23	3,767.31	5,687.52
	c) Research & Development	2,889.12	2,918.73	3,028.20	2,889.12	3,028.20	3,022.45
	d) Un allocated	56,698.57	43,436.44	44,219.74	56,698.57	44,219.74	39,125.31
	TOTAL	139,594.92	124,561.73	108,633.88	139,594.92	108,633.88	117,501.88
	SEGMENT LIABILITIES :						
	a) Manufacturing (CRAMS)	17,849.98	11,100.58	9,282.73	17,849.98	9,282.73	9,189.76
	b) Services (DDDSS)	648.76	273.05	473.46	648.76	473.46	641.72
	c) Research & Development	2,136.52	1,610.78	1,669.94	2,136.52	1,669.94	1,592.07
	d) Un allocated	1,362.26	1,197.17	949.14	1,362.26	949.14	829.03
	TOTAL	21,997.52	14,181.58	12,375.27	21,997.52	12,375.27	12,252.58



PART - I		CONSOLIDATED						Rs. In Lakhs
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended	
		30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019	
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
1	Income							
	Revenue from operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44	
	Other Income	558.52	300.67	658.62	859.19	1,471.40	2,422.93	
	Total income	27,990.01	20,199.30	9,610.80	48,189.31	29,589.80	68,773.37	
2	Expenses							
	a) Cost of materials consumed	6,047.63	5,866.31	4,102.40	11,913.94	7,961.69	20,413.82	
	b) Purchases of stock-in-trade	-	-	-	-	-	-	
	c) Changes in inventories of finished goods, work-in-progress	3,057.82	(1,732.14)	(3,525.09)	1,325.68	(929.27)	(3,061.41)	
	d) Employee benefits expense	1,723.93	1,942.44	1,464.88	3,666.37	3,240.86	6,612.45	
	e) Finance costs	229.10	168.72	59.37	397.82	166.42	377.38	
	f) Depreciation and amortisation	559.08	555.03	556.05	1,114.11	1,106.86	2,214.05	
	g) Manufacturing Exps	2,762.42	2,534.68	2,493.06	5,297.10	4,778.56	9,982.32	
	h) R & D Exps	2,279.38	4,285.71	2,573.37	6,565.09	5,349.17	11,985.07	
	i) Other Expenses	1,364.88	1,057.26	816.15	2,422.14	2,148.43	4,375.37	
	Total expenses	18,024.24	14,678.01	8,540.19	32,702.25	23,822.72	52,899.05	
3	Profit before exceptional items , Tax (1-2)	9,965.77	5,521.29	1,070.61	15,487.06	5,767.08	15,874.32	
4	Exceptional Items	-	-	-	-	-	-	
5	Profit before Tax (3-4)	9,965.77	5,521.29	1,070.61	15,487.06	5,767.08	15,874.32	
6	Tax Expenses							
	a) Current tax	3,645.51	3,483.61	513.83	7,130.12	1,762.97	4,604.23	
	b) Deferred tax	(10.94)	(583.22)	170.18	(594.16)	1,015.09	2,575.78	
7	Net Profit/ (Loss) for the period/year(7-8)	6,331.20	2,620.90	386.60	8,951.10	2,989.02	8,694.31	
8	Other Comprehensive Income							
8.a	(i) Items that will not be reclassified to profit or loss	(5.29)	(5.29)	(10.59)	(10.58)	(21.17)	(21.16)	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.85	1.85	3.67	3.70	7.33	7.39	
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	
	Total other Comprehensive Income	(3.44)	(3.44)	(6.92)	(6.88)	(13.84)	(13.77)	
9	Total Comprehensive Income for the period (9 + 10)	6,327.76	2,617.46	379.68	8,944.22	2,975.18	8,680.54	
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	
11	Other Equity	91,008.57	84,178.15	78,400.98	91,008.57	78,400.98	81,826.56	
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :							
	a) Basic	4.97	2.06	0.30	7.03	2.35	6.83	
	b) Diluted	4.97	2.06	0.30	7.03	2.35	6.83	
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)		



PART - II		CONSOLIDATED					Rs. In Lakhs
PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended	
	30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019	
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
1 SEGMENT REVENUE :-							
a) Manufacturing (CRAMS)	26,709.93	19,616.35	8,087.96	46,326.28	26,112.18	61,362.91	
b) Services (DDDSS)	721.56	282.28	864.22	1,003.84	2,006.22	4,987.53	
c) Research & Development	-	-	-	-	-	-	
TOTAL	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44	
Less Inter segment Revenue	-	-	-	-	-	-	
Net Sales from Operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44	
2 SEGMENT RESULTS :-							
Profit/(Loss) before tax and interest:							
a) Manufacturing (CRAMS)	12,518.68	10,587.57	3,185.49	23,106.25	10,211.08	26,330.25	
b) Services (DDDSS)	100.53	60.20	439.12	160.73	1,197.68	2,551.33	
c) Research & Development	(2,197.21)	(4,367.88)	(2,573.37)	(6,565.09)	(5,349.16)	(11,985.07)	
TOTAL	10,422.00	6,279.89	1,051.24	16,701.89	6,059.60	16,896.51	
Less: i) Interest	113.14	84.05	62.29	197.19	98.26	199.02	
ii) Other Un-allocable expenditure/(Income), net	343.09	674.55	(81.66)	1,017.64	194.26	823.17	
Total Profit Before Tax	9,965.77	5,521.29	1,070.61	15,487.06	5,767.08	15,874.32	
3 SEGMENT ASSETS :							
a) Manufacturing (CRAMS)	73,686.97	71,575.12	57,203.42	73,686.97	57,203.42	69,668.49	
b) Services (DDDSS)	5,651.55	5,604.44	3,745.49	5,651.55	3,745.49	5,687.52	
c) Research & Development	3,587.69	4,055.30	3,501.11	3,587.69	3,501.11	3,022.45	
d) Un allocated	40,778.22	28,605.45	32,706.55	40,778.22	32,706.55	25,510.28	
TOTAL	123,704.43	109,840.31	97,156.57	123,704.43	97,156.57	103,888.74	
SEGMENT LIABILITIES :							
a) Manufacturing (CRAMS)	18,665.47	8,798.99	9,092.14	18,665.47	9,092.14	9,912.30	
b) Services (DDDSS)	677.73	216.43	462.31	677.73	462.31	688.83	
c) Research & Development	5,277.36	9,118.52	3,058.61	5,277.36	3,058.61	3,388.76	
d) Un allocated	1,508.70	950.40	952.42	1,508.70	952.42	910.98	
TOTAL	26,129.26	19,084.34	13,565.48	26,129.26	13,565.48	14,900.87	

1) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th Nov 2019 and the same has been reviewed by the Statutory Auditors.

2) The Company is in the process of evaluating the impact of newly introduced Sec.115BAA of the Taxation Laws (Amendments) Ordinance, 2019.

3) The acquisition of Assets and Liabilities in RISING PHARMA HOLDINGS, Inc., under the US Bankruptcy Code are still in process. Hence, the company did not consider RISING PHARMA HOLDINGS, Inc. for consolidation.

4) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

Venkata Jasti

VENKAT JASTI

Chairman & CEO

DIN: 00278028

Place : Hyderabad

Date : 14th Nov ' 2019



SUVEN LIFE SCIENCES LIMITED

Unaudited Standalone Statement of Cash flows for the half year ended 30th September, 2019

(Rs.In lakhs, unless otherwise stated)

Particulars	Six months ended 30 September 2019	Six months ended 30 September 2018
A. Cash flow from operating activities		
Profit before tax	19,485.64	8,463.24
Adjustments :		
Depreciation and amortisation expense	1,346.85	1,282.07
Interest Income	(19.20)	(18.62)
Finance Cost	316.17	165.88
Gain on sale of Current Investment	(88.21)	(118.86)
Fair value gain on financial instruments at fair value through profit or loss	(113.98)	(815.41)
Loss/(Profit) on disposal of Property, plant & equipment	(8.00)	-
Operating profit before working capital changes	20,919.27	8,958.29
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(1,260.22)	(107.24)
Inventories	478.47	(54.29)
Other non current financial assets	(10.19)	(1.03)
Other non current assets	(885.16)	(2,124.60)
Other current financial assets	(21.71)	(4.58)
Other current assets	(1,049.49)	592.37
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(1,160.21)	(1,309.45)
Long term provisions	-	13.75
Other non-current liabilities	(14.53)	(14.53)
Short term provision	119.42	53.58
Other financial liabilities	261.40	1,842.78
Other current liabilities	(194.10)	(92.73)
Cash generated from operating activities	17,182.96	7,752.32
Income taxes paid (net of refunds)	972.42	2,334.71
Net Cash flows from operating activities	(A) 16,210.54	5,417.62
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(3,145.31)	(3,894.92)
Proceeds from sale of Property, plant & equipment	21.43	-
Changes in Investments	(27,020.04)	(1,340.55)
Sale/(purchase) of mutual funds	13,700.00	(838.66)
Bank balances not considered as cash and cash equivalents	(2.37)	5.09
Interest received	19.20	18.62
Net cash flow from /(used in) investing activities	(B) (16,427.09)	(6,050.41)
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	17.68	(25.36)
(Repayment)/Proceeds from short term borrowings	4,958.66	581.15
Finance Cost	(316.17)	(165.88)
Net cash flow from /(used In) financing activities	(C) 4,660.17	389.91
Net increase/(decrease) in cash and cash equivalents	(A+B+C) 4,443.62	(242.89)
Cash and cash equivalents as at the beginning of the year	1,090.74	1,342.59
Cash and cash equivalents at the end of the year	5,534.36	1,099.70
Cash and cash equivalents	5,534.36	1,099.70
	5,534.36	1,099.70



By Order of the Board
Suvén Life Sciences Limited

Venkaiah Jasti
Venkateswarlu Jasti
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : 14th Nov, 2019

SUVEN LIFE SCIENCES LIMITED

Unaudited Consolidated Statement of Cash flows for the half year ended 30 September 2019

(Rs.In lakhs, unless otherwise stated)

Particulars	Six months ended 30 September 2019	Six months ended 30 September 2018
A. Cash flow from operating activities		
Profit before tax	15,487.06	5,767.08
Adjustments :		
Depreciation and amortisation expense	1,346.85	1,282.07
Interest Income	(19.20)	(18.62)
Finance Cost	397.83	166.42
Gain on sale of Current Investment	(88.21)	(118.86)
Fair value gain on financial instruments at fair value through profit or loss	(113.98)	(815.41)
Loss/(Profit) on disposal of Property, plant & equipment	(8.00)	-
Operating profit before working capital changes	17,002.36	6,262.68
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(1,260.22)	(107.24)
Inventories	478.47	(54.29)
Other non current financial assets	(10.24)	(1.22)
Other non current assets	(885.16)	(2,124.60)
Other current financial assets	(4.08)	(4.58)
Other current assets	(1,049.49)	592.37
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(1,160.21)	(1,309.45)
Long term provisions	-	13.75
Other non-current liabilities	(14.53)	(14.53)
Short term provision	119.42	53.58
Other financial liabilities	(1,780.16)	2,635.35
Other current liabilities	(194.10)	(92.73)
Cash generated from operating activities	11,242.06	5,849.09
Income taxes paid (net of refunds)	972.42	2,334.71
Net Cash flows from operating activities	(A) 10,269.64	3,514.39
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(3,145.31)	(3,894.92)
Proceeds from sale of Property, plant & equipment	21.43	-
Changes in Investments	(24,675.00)	-
Sale/(purchase) of mutual funds	13,700.00	(838.66)
Foreign currency translation reserve	237.78	(42.03)
Bank balances not considered as cash and cash equivalents	(2.37)	5.09
Interest received	19.20	18.62
Net cash flow from / (used in) investing activities	(B) (13,844.27)	(4,751.89)
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	17.68	(25.36)
(Repayment)/Proceeds from short term borrowings	8,483.66	581.15
Finance Cost	(397.83)	(166.42)
Net cash flow from / (used in) financing activities	(C) 8,103.51	389.36
Net increase/(decrease) in cash and cash equivalents	(A+B+C) 4,528.88	(848.14)
Cash and cash equivalents as at the beginning of the year	1,113.04	2,031.68
Cash and cash equivalents at the end of the year	5,641.92	1,183.53
Cash and cash equivalents	5,641.92	1,183.53
	5,641.92	1,183.53



By Order of the Board
Suven Life Sciences Limited

Venkateswarlu Jasti
Venkateswarlu Jasti
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : 14th Nov, 2019



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30/09/2019	31/03/2019	30/09/2019	31/03/2019
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	28,166.58	29,056.22	28,166.58	29,056.22
(b) Capital Work-in-Progress	13,800.40	11,108.68	13,800.40	11,108.68
(c) Other Intangible Assets	251.45	268.50	251.45	268.50
(d) Financial Assets				
I. Investments	40,664.43	13,644.38	24,682.06	7.05
II. Loans	7.34	7.22	7.34	7.22
III. Other Financial Assets	447.48	437.42	449.43	439.31
(e) Deferred tax assets (net)	-	-	-	-
(f) Other non current assets	1,565.09	679.94	1,565.09	679.94
Total Non-Current assets	84,902.77	55,202.36	68,922.35	41,566.92
2 Current assets				
(a) Inventories	15,231.36	15,709.83	15,231.36	15,709.83
(b) Financial Assets				
I. Investments	9,501.10	22,998.92	9,501.10	22,998.92
II. Trade Receivables	16,274.85	15,014.63	16,274.85	15,014.63
III. Cash and Cash equivalents	5,534.36	1,090.74	5,641.92	1,113.04
IV. Bank balances other than (III) above	247.52	245.14	247.52	245.14
V. Loans	33.18	11.47	15.55	11.47
VI. Other Financial assets	0.28	0.28	0.28	0.28
(c) Current Tax asset (net)	-	408.50	-	408.50
(d) Other current assets	7,869.50	6,820.01	7,869.50	6,820.01
Total Current assets	54,692.15	62,299.52	54,782.08	62,321.82
TOTAL - ASSETS	139,594.92	117,501.88	123,704.43	103,888.74
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	1,272.82	1,272.82	1,272.82	1,272.82
(b) Other Equity	111,030.80	98,088.00	91,008.57	81,826.56
Equity attributable to owners of the company	112,303.62	99,360.82	92,281.39	83,099.38
2 LIABILITIES				
(a) Financial Liabilities				
I. Borrowings	195.21	177.53	195.21	177.53
(b) Provisions	743.16	743.16	743.16	743.16
(c) Deferred tax Liabilities (net)	4,294.24	4,892.10	4,294.24	4,892.10
(d) Other non current liabilities	61.17	75.69	61.17	75.70
Total non-current liabilities	5,293.78	5,888.48	5,293.78	5,888.49
Current liabilities				
(a) Financial Liabilities				
I. Borrowings	8,487.90	3,529.24	12,013.90	3,530.24
II. Trade payables				
a) To Micro & Small Enterprises	755.71	73.22	755.71	73.22
b) Other than Micro & Small Enterprises	4,150.15	5,992.86	4,150.15	5,992.86
III. Other Financial Liabilities	2,098.45	1,837.06	2,704.19	4,484.35
(b) Current Tax liabilities (Net)	5,749.20	-	5,749.20	-
(c) Other Current liabilities	397.08	591.18	397.08	591.18
(d) Provision Employee benefits	359.03	229.02	359.03	229.02
Sub-total - Current liabilities	21,997.52	12,252.58	26,129.26	14,900.87
Total Liabilities	27,291.30	18,141.06	31,423.04	20,789.36
TOTAL - EQUITY AND LIABILITIES	139,594.92	117,501.88	123,704.43	103,888.74
For Suven Life Sciences Ltd				
Place : Hyderabad			Venkat Jasti	
Date: 14th Nov, 2019			Chairman & CEO	



Ref No.LR/SLSL003/2019-20

Independent Auditor's Review Report on Unaudited Quarterly and Year to date Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED


We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No:5, Banjara Hills, Hyderabad-500034, Telangana for the quarter ended September 30, 2019 and year to date results for the period from April 01, 2019 to September 30, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended, read with SEBI Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular'). Attention is drawn to the fact that the consolidated figures for net cash flows for the corresponding period from April 01, 2018 to September 30, 2018, as reported in these unaudited standalone financial results have been approved by the Board of Directors of the company, but have not been subjected to review.


This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **TUKARAM & CO LLP**
Chartered Accountants
(Firm Registration No.004436S)


(RAJENDER REDDY K)
P A R T N E R
M.No.231834
UDIN: 19231834AAAACU4847



Place: Hyderabad
Date: November 14, 2019



Ref No.LR/SLSL004/2019-20:

Independent Auditor's Review Report on the Unaudited Quarterly and Year to date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


To
The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of SUVEN LIFE SCIENCES LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2019 and year to date results for the period from April 01, 2019 to September 30, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Regulation"), read with SEBI Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ("the Circular"). Attention is drawn to the fact that the consolidated figures for net cash flows for the corresponding period from April 01, 2018 to September 30, 2018, as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors of the company, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Pharmaceuticals Limited	Wholly Owned Subsidiary
Suven Neuro Sciences Inc	Wholly Owned Subsidiary
Suven Pharma Inc	Wholly Owned Subsidiary
Rising Pharma Holdings Inc	Associate



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of branch auditor and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information/ financial results of USA branch of parent included in the unaudited standalone financial results of the Company whose interim financial information/ financial results reflect total assets of Rs 76.33 lakhs as at 30th September, 2019 and total revenue of Rs.-Nil- for the half ended 30th September, 2019. The interim financial information/ financial results of this branch have been audited by the branch auditor, whose reports have been furnished to us, and our opinion in so far as it relates to the amounts and disclosures included in respect of these branches, is based solely on the report of such branch auditor.


We did not review the interim financial information/ financial results of two subsidiaries included in the consolidated unaudited financial results, whose interim financial information/ financial results reflect total assets of Rs. 24,783.98 lakhs as at 30th September 2019, total revenue of Rs.Nil, total expenses of Rs.3,997.78 lakhs and total net loss after tax of Rs. 3,997.78 lakhs for the half year ended 30th September, 2019, as considered in the consolidated unaudited financial results. These interim financial information/ financial results have been reviewed by other auditors, whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiaries, is based solely on the report of the other auditor.

Our conclusion on the Statement is not modified in respect of the above matters.


7. We draw your attention to Note no. 3 in the statement regarding preparation of financial results, that the Company has invested thirty five million US Dollars in Rising Pharma Holdings Inc. through its wholly owned subsidiary, Suven Pharma Inc, during April, 2019. As per explanation provided by the management it is understood that the acquisition of assets and liabilities under US Bankruptcy code is still under process, hence company did not consider Rising Pharma Holdings Inc. for the consolidation.

Our conclusion on the Statement is not modified in respect of the above matter.

For **TUKARAM & CO LLP**
Chartered Accountants
(Firm Registration No.004436S)



(RAJENDER REDDY K)
P A R T N E R
M.No. 231834
UDIN: 19231834AAAACV1728



Place: Hyderabad
Date: November 14, 2019

News Release

Suven Income at INR 4819 Mn; PAT at INR 1294 Mn for the half year ended September 2019

HYDERABAD, INDIA (November 14, 2019)—Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS), today announced its Un-audited Financial Results for the quarter ended 30th September 2019. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th November, 2019 at Hyderabad.

Financial Highlights for the Half year ended September' 2019:

Growth in revenue	INR 4819 Mn vs INR 2949 Mn - up by 62.86%
Growth in PAT	INR 1294 Mn vs INR 567 Mn - up by 128.21%
Growth in EBIDTA	INR 2092 Mn vs INR 974 Mn - up by 114.83%

Financial Highlights for the 2nd Quarter ended September' 2019 (QoQ):

Growth in revenue	INR 2799 Mn vs INR 2020 Mn – up by 38.57%
Growth in PAT	INR 723 Mn vs INR 571 Mn - up by 26.50%
Growth in EBIDTA	INR 1161 Mn vs INR 930 Mn - up by 24.81%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of INR 278 Mn (5.76% on income) for the half year ended September 2019.

Update on patents during this period can be viewed at:

<http://suven.com/Patentupdates.aspx>

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com